Get the Stockscreener App
75.45
0.87%
0.65
After Hours:
75.45
Incyte Corp stock is traded at $75.45, with a volume of 1.14M.
It is up +0.87% in the last 24 hours and up +15.95% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$74.80
Open:
$75
24h Volume:
1.14M
Relative Volume:
0.57
Market Cap:
$14.48B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
39.92
EPS:
1.89
Net Cash Flow:
$16.80M
1W Performance:
+6.19%
1M Performance:
+15.95%
6M Performance:
+31.65%
1Y Performance:
+42.71%
1-Day Range:
$74.75
$76.14
1-Week Range:
$69.30
$76.14
52-Week Range:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
75.45 | 14.48B | 4.08B | 32.48M | 16.80M | 1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Glenmede Trust Co. NA Trims Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Massachusetts Financial Services Co. MA Invests $4.74 Million in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Announces Updated Presentation Time for Upcoming Investor Conference - Yahoo Finance
INCY (Incyte) Free Cash Flow per Share : $0.17 (TTM As of Sep. 2024) - GuruFocus.com
Commerce Bank Buys New Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
PNC Financial Services Group Inc. Purchases 9,083 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: pipeline progress faces patent cliff pressure - Investing.com
INCY (Incyte) Long-Term Debt & Capital Lease Obligation : $28 Mil (As of Sep. 2024) - GuruFocus.com
Incyte shares target lifted, buy rating on povorcitinib sales outlook - Investing.com
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting - Yahoo Finance
Incyte : Bull market turns 8historical facts and figures - Marketscreener.com
Analysts Set Incyte Co. (NASDAQ:INCY) Price Target at $77.16 - MarketBeat
Intech Investment Management LLC Decreases Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Banco Santander S.A. - MarketBeat
Cypress Capital Group Invests $971,000 in Incyte Co. (NASDAQ:INCY) - MarketBeat
Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock - Insider Monkey
Incyte Co. (NASDAQ:INCY) Stock Position Lessened by Empowered Funds LLC - MarketBeat
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis, GlaxoSmithKline, Janssen Research & Development - Barchart
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
What Are Wall Street Analysts' Target Price For Incyte Stock? - Barchart
What Are Wall Street Analysts' Target Price for Incyte Stock? - Inkl
Big Moves: November 19, 2024 - substack.com
Merck (MRK) Eyes Incyte (INCY) for Possible Acquisition - Value the Markets
Incyte Sinks On Setback For 2 Drugs Acquired In $750M Buyout: Retail Chatter Hits One-Year High - MSN
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
U.S. Indexes Ended Tuesday Mixed As Super Micro Computer Led, Incyte Lagged - Barron's
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. - Yahoo! Voices
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges - AOL
BMO keeps Incyte stock at underperform, price target at $52 - Investing.com
Incyte (NASDAQ:INCY) Shares Gap DownHere's Why - MarketBeat
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Yahoo Finance
Merck ‘linked’ to takeover bid for Incyte, Sky News says - TipRanks
Incyte seesaws on report of potential Merck takeover interest (NASDAQ:INCY) - Seeking Alpha
What's Going On With Incyte Shares Tuesday? - Benzinga
Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock. - MSN
Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study - Yahoo Finance
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Incyte Faces Challenges but Remains Focused on Strategic Growth - Yahoo Finance
Incyte sinks on setback for drugs acquired in $750M buyout - BioPharma Dive
Incyte's (INCY) "Neutral" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Incyte price target lowered to $86 from $90 at BofA - TipRanks
RBC maintains sector perform on Incyte shares, cuts target following '262 pause - Investing.com
One Paused, One Dropped: Incyte’s Skin Drug Acquisitions Hit Problems - Citeline News & Insights
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble - BioSpace
Incyte culls one Escient-acquired dermatology programme, pauses another - FirstWord Pharma
After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more - Investing.com
Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP - TipRanks
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
3.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):